Collegium Pharmaceutical, Inc. (COLL): Price and Financial Metrics

Collegium Pharmaceutical, Inc. (COLL): $22.02

0.06 (-0.27%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

B

Add COLL to Watchlist
Sign Up

COLL Price/Volume Stats

Current price $22.02 52-week high $30.22
Prev. close $22.08 52-week low $15.58
Day low $22.00 Volume 53,314
Day high $22.61 Avg. volume 376,142
50-day MA $23.10 Dividend yield N/A
200-day MA $23.92 Market Cap 764.84M

COLL Stock Price Chart Interactive Chart >

COLL POWR Grades

  • COLL scores best on the Quality dimension, with a Quality rank ahead of 94.57% of US stocks.
  • COLL's strongest trending metric is Growth; it's been moving down over the last 177 days.
  • COLL ranks lowest in Momentum; there it ranks in the 9th percentile.

COLL Stock Summary

  • The price/operating cash flow metric for COLLEGIUM PHARMACEUTICAL INC is higher than only 12.68% of stocks in our set with a positive cash flow.
  • Over the past twelve months, COLL has reported earnings growth of -507.1%, putting it ahead of just 2.92% of US stocks in our set.
  • Revenue growth over the past 12 months for COLLEGIUM PHARMACEUTICAL INC comes in at 71.27%, a number that bests 92.47% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to COLL, based on their financial statements, market capitalization, and price volatility, are XPOF, GHL, USIO, AMG, and PIPR.
  • Visit COLL's SEC page to see the company's official filings. To visit the company's web site, go to www.collegiumpharma.com.

COLL Valuation Summary

  • In comparison to the median Healthcare stock, COLL's price/sales ratio is 26.32% lower, now standing at 1.4.
  • COLL's price/sales ratio has moved NA NA over the prior 102 months.

Below are key valuation metrics over time for COLL.

Stock Date P/S P/B P/E EV/EBIT
COLL 2023-09-22 1.4 3.9 -69.3 16.3
COLL 2023-09-21 1.5 3.9 -70.2 16.4
COLL 2023-09-20 1.5 3.9 -70.9 16.5
COLL 2023-09-19 1.5 3.9 -70.2 16.4
COLL 2023-09-18 1.4 3.9 -69.6 16.3
COLL 2023-09-15 1.5 3.9 -70.5 16.5

COLL Growth Metrics

    Its 3 year net income to common stockholders growth rate is now at 241.79%.
  • Its 4 year net income to common stockholders growth rate is now at 87.63%.
  • The 3 year net cashflow from operations growth rate now stands at -56.03%.
COLL's revenue has moved up $64,974,000 over the prior 33 months.

The table below shows COLL's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 361.675 94.103 -42.837
2022-06-30 313.505 68.588 -35.248
2022-03-31 272.898 57.672 42.786
2021-12-31 276.868 103.557 71.517
2021-09-30 325.777 89.936 103.509
2021-06-30 326.11 106.862 106.749

COLL's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • COLL has a Quality Grade of B, ranking ahead of 83.9% of graded US stocks.
  • COLL's asset turnover comes in at 0.493 -- ranking 87th of 681 Pharmaceutical Products stocks.
  • IBIO, IRWD, and COCP are the stocks whose asset turnover ratios are most correlated with COLL.

The table below shows COLL's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.493 0.608 0.369
2021-03-31 0.498 0.612 0.422
2020-12-31 0.483 0.580 0.341
2020-09-30 0.552 0.522 0.367
2020-06-30 0.638 0.460 0.266
2020-03-31 0.772 0.391 2.336

COLL Price Target

For more insight on analysts targets of COLL, see our COLL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $26.71 Average Broker Recommendation 1.56 (Moderate Buy)

Collegium Pharmaceutical, Inc. (COLL) Company Bio


Collegium Pharmaceuticals is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx technology platform for the treatment of chronic pain and other diseases. The company was founded in 2002 and is based in Canton, Massachusetts.


COLL Latest News Stream


Event/Time News Detail
Loading, please wait...

COLL Latest Social Stream


Loading social stream, please wait...

View Full COLL Social Stream

Latest COLL News From Around the Web

Below are the latest news stories about COLLEGIUM PHARMACEUTICAL INC that investors may wish to consider to help them evaluate COLL as an investment opportunity.

Collegium Announces 10 Poster Presentations at PAINWeek Conference 2023

STOUGHTON, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that 10 poster presentations highlighting data regarding its diversified pain portfolio will be presented at PAINWeek Conference 2023, being held in Las Vegas, NV from September 5–8, 2023. “Collegium is dedicated to responsible pain management an

Yahoo | August 28, 2023

Collegium Announces Extension of Nucynta Regulatory Exclusivity through July 2026

STOUGHTON, Mass., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted New Patient Population exclusivity for Nucynta®, an immediate release formulation of tapentadol. This grant extends the period of U.S. exclusivity for Nucynta from June 27, 2025 to July

Yahoo | August 24, 2023

Collegium Announces $50 Million Accelerated Share Repurchase Program

STOUGHTON, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $50 million of the Company’s common stock. Collegium will execute the ASR as part of the $100 million share repurchase program authorized

Yahoo | August 7, 2023

Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q2 Earnings

Although the revenue and EPS for Collegium Pharmaceutical (COLL) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Yahoo | August 4, 2023

Collegium Pharmaceutical (COLL) Q2 Earnings Beat Estimates

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 3.28% and 1.76%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 3, 2023

Read More 'COLL' Stories Here

COLL Price Returns

1-mo -6.26%
3-mo 1.06%
6-mo -8.21%
1-year 42.43%
3-year 19.09%
5-year 49.39%
YTD -5.09%
2022 24.20%
2021 -6.74%
2020 -2.67%
2019 19.86%
2018 -6.99%

Continue Researching COLL

Here are a few links from around the web to help you further your research on Collegium Pharmaceutical Inc's stock as an investment opportunity:

Collegium Pharmaceutical Inc (COLL) Stock Price | Nasdaq
Collegium Pharmaceutical Inc (COLL) Stock Quote, History and News - Yahoo Finance
Collegium Pharmaceutical Inc (COLL) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!